Sanofi SA at Citi BioPharma Conference (Virtual) Transcript
So welcome again. Good morning or good afternoon, wherever you're coming from. It's Pete here from the Citi Pharma team. I'm delighted to be introducing Frank Nestle, who is the CSO at Sanofi and Head of Research. We also have with us the IR team.
For those who have been on the conference, it's now day 3, 3 or 4. I'm sure you're hearing me say this, but I will, as always, I'm here to moderate, not monopolize. (Operator Instructions) I will make sure there's questions that I'll put it to Frank. This is going to be pure Q&A rather than prepared slides or commentary because there's a lot to go through. So maybe Frank, I'm kicking off -- sorry to interrupt you there.
Questions & Answers
So maybe just to kick off, before we get into discussing recent news flow or specific assets, maybe you could just set the scene because we're coming up to a 2-year anniversary of the CMD, where the management team laid out the sort of new vision for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |